Form S-3 ANAPTYSBIO, INC

Go back to Form S-3 ANAPTYSBIO, INC

AnaptysBio (ANAB) PT Lowered to $52 at H.C. Wainwright

November 6, 2024 6:12 AM UTC

H.C. Wainwright analyst Emily Bodnar lowered the price target on AnaptysBio (NASDAQ: ANAB) to $52.00 (from $55.00) while maintaining a Buy rating.

The analyst comments "3Q24 financial recap; lowering PT to $52 from $55. AnaptysBio had 3Q24 total operating expenses of $52.8M, which were slightly... More

AnaptysBio (ANAB) PT Lowered to $45 at Leerink Partners

November 6, 2024 5:58 AM UTC

Leerink Partners analyst David Risinger lowered the price target on AnaptysBio (NASDAQ: ANAB) to $45.00 (from $47.00) while maintaining a Outperform rating.

The analyst comments " Bottom Line: ANAB reported 3Q results and stated that there have been no blinded safety issues to date with either its BTLA... More

Anaptysbio (ANAB) Files $500M Mixed Shelf

November 5, 2024 4:30 PM UTC

Anaptysbio (NASDAQ: ANAB) has filed $500,000,000 mixed shelf of:

Common Stock, Preferred Stock, Debt Securities, Warrants, Subscription Rights and Units

... More